These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37993269)

  • 1. Elobixibat improves rectal sensation in patients with chronic constipation aged ≥60 years: a randomised placebo-controlled study.
    Manabe N; Umeyama M; Ishizaki S; Ota T; Kuratani S; Katsumata R; Fujita M; Haruma K; Camilleri M
    BMJ Open Gastroenterol; 2023 Nov; 10(1):. PubMed ID: 37993269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
    Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific inhibition of bile acid transport alters plasma lipids and GLP-1.
    Rudling M; Camilleri M; Graffner H; Holst JJ; Rikner L
    BMC Cardiovasc Disord; 2015 Jul; 15():75. PubMed ID: 26197999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.
    Nakajima A; Seki M; Taniguchi S
    J Gastroenterol; 2018 Apr; 53(4):525-534. PubMed ID: 28840422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elobixibat for the treatment of constipation.
    Chedid V; Vijayvargiya P; Camilleri M
    Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):951-960. PubMed ID: 30204504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota.
    Misawa N; Higurashi T; Takatsu T; Iwaki M; Kobayashi T; Yoshihara T; Ashikari K; Kessoku T; Fuyuki A; Matsuura T; Ohkubo H; Usuda H; Wada K; Naritaka N; Takei H; Nittono H; Matsumoto M; Honda A; Nakajima A; Camilleri M
    Aliment Pharmacol Ther; 2020 Sep; 52(5):821-828. PubMed ID: 32687674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation.
    Nakajima A; Ishizaki S; Matsuda K; Kurosu S; Taniguchi S; Gillberg PG; Mattsson JP; Hasunuma T; Camilleri M
    J Gastroenterol Hepatol; 2022 May; 37(5):883-890. PubMed ID: 35168298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: Elobixibat: a novel treatment for chronic constipation.
    Khanna L; Camilleri M
    Aliment Pharmacol Ther; 2021 Jan; 53(2):234-242. PubMed ID: 33296518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Elobixibat in Parkinson's Disease with Chronic Constipation: CONST-PD Study.
    Hatano T; Oyama G; Shimo Y; Ogaki K; Nishikawa N; Nakamura R; Tsunemi T; Ogawa T; Eguchi H; Daida K; Kurita N; Ueno SI; Fukae J; Sako W; Shiina K; Nakajima S; Oji Y; Wakamori R; Saiki S; Nishioka K; Okuzumi A; Taniguchi D; Takeshige-Amano H; Fuse A; Nakajima A; Kano M; Kamo H; Yamashita Y; Shindo A; Yanagisawa N; Hattori N
    Mov Disord Clin Pract; 2024 Apr; 11(4):352-362. PubMed ID: 38264844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson's disease with chronic constipation: a multicentre, placebo-controlled, randomised, double-blind, parallel-group stud (CONST-PD).
    Hatano T; Oyama G; Shimo Y; Ogaki K; Nishikawa N; Fukae J; Nakamura R; Kurita N; Tsunemi T; Oji Y; Saiki S; Nishioka K; Takeshige-Amano H; Taniguchi D; Ogawa T; Kamo H; Eguchi H; Fuse A; Nakajima A; Kano M; Nakajima S; Yanagisawa N; Hattori N
    BMJ Open; 2022 Feb; 12(2):e054129. PubMed ID: 35149566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial.
    Kumagai Y; Amano H; Sasaki Y; Nakagawa C; Maeda M; Oikawa I; Furuie H
    Br J Clin Pharmacol; 2018 Oct; 84(10):2393-2404. PubMed ID: 29959787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation.
    Tanaka K; Kessoku T; Yamamoto A; Takahashi K; Kasai Y; Ozaki A; Iwaki M; Kobayashi T; Yoshihara T; Misawa N; Kato T; Arimoto J; Fuyuki A; Sakai E; Higurashi T; Chiba H; Hosono K; Yoneda M; Iwasaki T; Kurihashi T; Nakatogawa M; Suzuki A; Taguri M; Oyamada S; Ariyoshi K; Kobayashi N; Ichikawa Y; Nakajima A
    BMJ Open; 2022 May; 12(5):e060704. PubMed ID: 35636802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological characteristics and clinical study results of ileal bile acid transporter inhibitor elobixibat (GOOFICE
    Ikeda N; Taniguchi S; Seki M
    Nihon Yakurigaku Zasshi; 2019; 153(3):129-138. PubMed ID: 30867382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan.
    Nakajima A; Taniguchi S; Kurosu S; Gillberg PG; Mattsson JP; Camilleri M
    Neurogastroenterol Motil; 2019 May; 31(5):e13571. PubMed ID: 30793431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Elobixibat in Patients with Diabetes and Concomitant Chronic Constipation: an 8-week, Prospective, Single-center, Single-arm Study.
    Hishida Y; Nagai Y; Tsukiyama H; Nakamura Y; Nakagawa T; Ishizaki S; Tanaka Y; Sone M
    Adv Ther; 2022 Sep; 39(9):4205-4217. PubMed ID: 35867276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study.
    Kamei D; Kamei Y; Nagano M; Mineshima M; Nitta K; Tsuchiya K
    BMC Gastroenterol; 2020 Jan; 20(1):26. PubMed ID: 32005162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake.
    Ozaki A; Kessoku T; Kasai Y; Takeda Y; Okubo N; Iwaki M; Kobayashi T; Yoshihara T; Honda Y; Fuyuki A; Higurashi T; Ishiki H; Taguri M; Oyamada S; Kobayashi N; Nakajima A; Ichikawa Y
    Oncologist; 2021 Oct; 26(10):e1862-e1869. PubMed ID: 34180099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elobixibat for the treatment of constipation.
    Wong BS; Camilleri M
    Expert Opin Investig Drugs; 2013 Feb; 22(2):277-84. PubMed ID: 23215781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Comparison of Elobixibat and Lubiprostone Treatment in Patients with Chronic Constipation: A Propensity Score-Matched Analysis.
    Eguchi T; Yoshizaki T; Ikeoka S; Takagi M; Fujinami M; Matsuda T; Yamaguchi T; Nonaka T; Amioka S; Katayama N; Inoue K; Matsumoto M; Momose K; Sako T; Noda M; Morisawa T; Okada A
    Dig Dis; 2021; 39(4):341-350. PubMed ID: 33142288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of elobixibat and lubiprostone in Japanese patients with chronic constipation: a retrospective cohort study.
    Ooba N; Takahashi Y; Nagamura M; Takahashi M; Ushida M; Kawakami E; Kimura M; Sato T; Tokuyoshi J; Miyazaki C; Shimada M
    Expert Opin Drug Saf; 2021 Dec; 20(12):1553-1558. PubMed ID: 34281471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.